NCT02863354View on ClinicalTrials.gov

Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Proliferative Diabetic Retinopathy
Interventions
DRUG

Aflibercept

Intravitreal injection

Trial Locations (4)

77030

Retina Consultants of Houston/The Medical Center, Houston

77339

Retina Consultants of Houston, Kingwood

77384

Retina Consultants of Houston, The Woodlands

77494

Retina Consultants of Houston/Katy office, Katy

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Charles C Wykoff, PhD, MD

OTHER

NCT02863354 - Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter